Tharimmune announces positive target engagement with novel biparatopic pd-1/vegf and multispecific her2/her3 biologics leveraging proprietary epiclick technology

Bridgewater, nj / access newswire / march 4, 2025 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with hs1940, a dual-target multispecific biologic engineered to bind to both programmed death-1 (pd-1) and vascular endothelial growth factor (vegf) receptors. using its proprietary epiclick™ technology, a versatile multispecific antibody engineering platform, hs1940 represents a key expansion of tharimmune's product pipeline and underscores the company's commitment to addressing unmet needs.
THAR Ratings Summary
THAR Quant Ranking